“We are extremely pleased to partner with a global company of Itochu’s caliber and skills on these exciting product opportunities,” said Jeffrey M. Yordon, CEO, founder and chairman of the board of Sagent Pharmaceuticals, Inc.  “Sagent is committed to expanding its network of worldwide strategic partnerships to offer the most diverse and extensive pipeline of the highest quality injectable products to our hospital focused customers and we look forward to including ICF amongst our partners.”

“ICF looks forward to rapidly expanding our presence in the U.S. market,” said Jun Sato, ICF’s president and chief executive officer. “We believe that this collaboration combining ICF’s experience in the Japanese market with Sagent’s U.S. focused injectable selling and marketing capabilities is an optimal path toward achieving this objective.”

To Discover Injectables Excellence^® and learn more about Sagent, please visit www.SagentPharma.com.  

 

About Itochu Chemical Frontier Corporation

Itochu Chemical Frontier Corporation (ICF) is the core enterprise of Pharmaceutical & Life-science and Organic & Fine Chemical field in ITOCHU Corporation which is one of the largest trading houses in the world.  Pharmaceutical division of ICF has a global net work of resources for Active Pharmaceutical Ingredient (API) and Pharmaceutical Finished Products in the extensive pipeline from primary care to high potency pharmaceuticals such as antibiotic, anticancer and biologic products and supplies them to our worldwide business partners.

To learn more about Itochu Chemical Frontier, please visit  www.itcchem.co.jp/en/index.html